Breast cancer in young women and its impact on reproductive function

Human Reproduction Update

Volumn 15, Issue 3, 2009, Pages 323-339

  Hickey, M ^a   Peate, M ^b,c   Saunders, C M ^d   Friedlander, M ^b,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Breast cancer; Contraception; Fertility; Menopause; Pregnancy

Indexed keywords

ALPHA TOCOPHEROL; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CLONIDINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTRADIOL; ESTROGEN; FLUOROURACIL; GABAPENTIN; GESTAGEN; GONADORELIN DERIVATIVE; INHIBIN B; LETROZOLE; METHOTREXATE; MUELLERIAN INHIBITING FACTOR; PACLITAXEL; PAROXETINE; POLYCARBOPHIL; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; TESTOSTERONE; TRASTUZUMAB; UNINDEXED DRUG; VENLAFAXINE;

ADJUVANT THERAPY; AMENORRHEA; ARTICLE; ATROPHIC VAGINITIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CRYOPRESERVATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM POLYP; FERTILIZATION; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENITAL MALFORMATION; GONADOTOXICITY; GRANULOSA CELL; HOT FLUSH; HUMAN; HYPERPLASIA; HYPOACTIVE SEXUAL DESIRE DISORDER; INFERTILITY; INFERTILITY THERAPY; LYMPH NODE DISSECTION; MASTECTOMY; MENOPAUSAL SYNDROME; MENSTRUATION DISORDER; MULTIPLE CYCLE TREATMENT; NIGHT SWEAT; OVARIAN RESERVE; OVARY INSUFFICIENCY; OVERALL SURVIVAL; OVULATION INDUCTION; OVULATION INHIBITION; PLASTIC SURGERY; PRIORITY JOURNAL; PROGNOSIS; REPRODUCTION; REPRODUCTIVE TOXICITY; SALPINGOOOPHORECTOMY; SENTINEL LYMPH NODE BIOPSY; SEXUAL DYSFUNCTION; SURVIVAL RATE; VAGINA DISCHARGE; VAGINAL DRYNESS; VAGINAL PRURITUS; VAGINITIS;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CONTRACEPTION; FEMALE; HUMANS; INFERTILITY, FEMALE; MENOPAUSE; META-ANALYSIS AS TOPIC; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCTION; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 64649095467     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmn064     Document Type: Article

References (184)

1. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000;355 1869-1874.
2. Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative breast cancer. Breast Cancer Res 2004;6:240-245.
3. Alton J, Jacobs L, Fox K, Schuchter L, Domchek S, Glick J, Meadows A, DeMichele A. Chemotherapy-related amenorrhea (CRA) in breast cancer survivors: Impact of taxanes on ovarian function. Breast Cancer Res Treat 2004;88:S61-S62.
4. American Academy of Pediatrics. Work Group on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 1997; 100 1035-1039.
5. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008;26 3324-3330.
6. Anderson G, Limacher M, Assaf A, Bassford T, Beresford S, Black H, Bonds D, Brunner R, Brzyski R, Caan B et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004; 291 1701-1712.
7. Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 2006;21:2583-2592.
8. Andersen BL, Carpenter KM, Yang HC, Shapiro CL. Sexual well-being among partnered women with breast cancer recurrence. J Clin Oncol 2007;25:3151-3157.
9. Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R, Antoniou AC, Peock S, Evans G, Eccles D, Douglas F et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst 2006;98 535-544.
10. Arriagada R, Le MG, Guinebretiere JM, Dunant A, Rochard F, Tursz T. Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients. Ann Oncol 2003;14:1617-1622.
11. Averette HE, Mirhashemi R, Moffat FL. Pregnancy after breast carcinoma: the ultimate medical challenge. Cancer 1999;85:2301-2304.
12. Aviles A, Neri N. Hematological malignancies and pregnancy: A final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2001;2:173-177.
13. Axelrod D, Smith J, Kornreich D, Grinstead E, Singh B, Cangiarella J, Guth AA. Breast cancer in young women. J Am Coll Surg 2008; 206 1193-1203.
14. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: A prospective controlled study. J Clin Oncol 2008; 26:2630-2635.
15. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180:S312-S316.
16. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2008. doi:10.1016/ j.fertnstert.2007.12.044 (3 August 2008, date last accessed).
17. Bao T, Davidson NE. Adjuvant endocrine therapy for premenopausal women with early breast cancer. Breast Cancer Res 2007;9:115.
18. Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 1997;71:73-80.
19. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen: A lesson for oncologists. Cancer 2007; 109:832-839.
20. Barthelmes L, Gately CA. Tamoxifen and pregnancy. Breast 2004; 13:446-451.
21. Barthelmes L, Davidson LA, Gaffney C, Gateley CA. Pregnancy and breast cancer. BMJ 2005;330:1375-1378.
22. Barton D, Loprinzi C, Quella S, Sloan J, Pruthi S, Novotny P. Depomedroxyprogesterone acetate for hot flashes. J Pain Symptom Manage 2002;24:603-607.
23. Barton DL, Wender DB, Sloan JA, Dalton RJ, Balcueva EP, Atherton PJ, Bernath AMJ, DeKrey WL, Larson T, Bearden JD et al. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. J Natl Cancer Inst 2007;99:672-679.
24. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006;11(Suppl. 1):4-12.
25. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002;11:367-377.
26. Bentzon N, During M, Rasmussen BB, Mouridsen H, Kroman N. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 2008;122:1089-1094.
27. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: A systematic review. Int J Cancer 2007;121:225-231.
28. Biglia N, Cozzarella M, Cacciari F, Ponzone R, Roagna R, Maggiorotto F, Sismondi P. Menopause after breast cancer: A survey on breast cancer survivors. Maturitas 2003;45:29-38.
29. Blakely LJ, Buzdar AU, Lozada JA, Shullaih SA, Hoy E, Smith TL, Hortobagyi GN. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 2004; 100:465-469.
30. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007; 12:1044-1054.
31. Bordeleau L, Pritchard K, Goodwin P, Loprinzi C. Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review. Clin Ther 2007;29:230-241.
32. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006;12:685-718.
33. Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, Peock S, Eeles RA, Cook M, Chu C et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 2007; 25:3831-3836.
34. Bukulmez O, Arici A. Assessment of ovarian reserve. Curr Opin Obstet Gynecol 2004;16:231-237.
35. Burwell SR, Case LD, Kaelin C, Avis NE. Sexual problems in younger women after breast cancer surgery. J Clin Oncol 2006; 24:2815-2821.
36. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007;25:3985-3990.
37. Canney PA, Hatton MQ. The prevalence of menopausal symptoms in patients treated for breast cancer. Clin Oncol (R Coll Radiol) 1994; 6 297-299.
38. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004;5:283-291.
39. Carpenter S, Andrykowski AM, Cordova M. Hot flashes in postmenopausal women treated for breast carcinoma: Prevalence, severity, correlates, management and relation to quality of life. Cancer 1998;82 1682-1691.
40. Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008;107:167-180.
41. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, and ATAC Trialistsa9 Group. Quality of life of postmenopausal women in the ATAC ('Arimidex', tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273-284.
42. Chan SSC, Tam WH, YeoW, Yu MMY, Ng DPS,Wong AWY, Kwan WH, Yuen PM. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 2007; 114:1510-1515.
43. Chen Y, Thompson W, Semeciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 1999;8 855-861.
44. Chen Z, Maricic M, Bassford TL, Ritenbaugh C, Lopez AM, Leboff MS, Gass M, Barad D. Increased fracture risk among breast cancer survivors results from the women's health initiative. J Bone Miner Res 2003;18:S22-S22.
45. Chiarelli AM, Kirsh VA, Klar NS, Shumak R, Jong R, Fishell E, Yaffe MJ, Boyd NF. Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection. Cancer Epidemiol Biomarkers Prev 2006;15:1856-1862.
46. Clark S. Prophylactic tamoxifen. Lancet 1993;342:168.
47. Clark RM, Chua T. Breast cancer and pregnancy: The ultimate challenge. Clin Oncol (R Coll Radiol) 1989;1:11-18.
48. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 366:2087-2106.
49. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol 2007;8:119-127.
50. Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, Luini A, Veronesi P, Intra M, Orecchia R et al. Very young women (<35 years) with operable breast cancer: Features of disease at presentation. Ann Oncol 2002;13:273-279.
51. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes towards estrogen replacement therapy. J Clin Oncol 1995; 13 12737-12744.
52. Cullins SL, Pridjian G, Sutherland CM. Goldenhar's syndrome associated with tamoxifen given to the mother during gestation. JAMA 1994; 271:1905-1906.
53. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082.
54. Danforth DN Jr. How subsequent pregnancy affects outcome in women with a prior breast cancer. Oncology (Williston) 1991;5:23-30; discussion 30-21.
55. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol 2008; 26:44-53.
56. Degner LF, Kristjanson LJ, Bowman D, Sloan JA, Carriere KC, O'Neil J, Bilodeau B, Watson P, Mueller B. Information needs and decisional preferences in women with breast cancer. JAMA 1997; 277 1485-1492.
57. Del Bianco P, Zavagno G, Burelli P, Scalco G, Barutta L, Carraro P, Pietrarota P, Meneghini G, Morbin T, Tacchetti G et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: Results of the sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol 2008;34:508-513.
58. Demicheli R, Bonadonna G, Hrushesky WJM, Retsky MW, Valagussa P. Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour. Breast Cancer Res 2004;6:R689-R696.
59. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003;6:45-52.
60. Duffy CM, Allen SM, Clark MA. Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol 2005;23:766-773.
61. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. [erratum appears in N Engl J Med 1996 Apr 11;334(15):1003]. N Engl J Med 1995;333:1444-1455.
62. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
63. Early Breast Cancer Trialists' Collaborative Group, Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: Patient-level meta-analysis of randomised trials. Lancet 2008;371:29-40.
64. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005; 23 7491-7496.
65. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB, Shamseddine AI. Effects of young age at presentation on survival in breast cancer. BMC Cancer 2006;6:194.
66. Fallowfield LJ, Hall A, Maguire P, Baum M, A'Hern RP. Psychological effects of being offered choice of surgery for breast cancer. BMJ 1994; 309:448.
67. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004; 22:4261-4271.
68. Fellowes D, Fallowfield LJ, Saunders CM, Houghton J. Tolerability of hormone therapies for breast cancer: How informative are documented symptom profiles in medical notes for 'well-tolerated' treatments? Breast Cancer Res Treat 2001;66:73-81.
69. Fogelman I, Blake GM, Blamey R, Palmer M, Sauerbrei W, Schumacher M, Serin D, Stewart A, Wilpshaar W. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003;14:1001-1006.
70. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-695.
71. Gadducci A, Cosio S, Genazzani AR. Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol 2007;23 625-631.
72. Gallagher K. What should I do If I'm at High Risk for Breast Cancer? USA: Healthwise, 2007.
73. Ganz P, Hahn E. Implementing a survivorship care plan for patients with breast cancer. J Clin Oncol 2008;26:759-767.
74. Gebski V, Lagleva M, Keech A, Simes J, Langlands AO. Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: A clinical perspective [erratum appears in J Natl Cancer Inst 2006;98(12):876]. J Natl Cancer Inst 2006;98:26-38.
75. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25 3194-3197.
76. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802.
77. Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost MH, Grant CS, Donohue JH, Woods JE et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93:1633-1637.
78. Helewa M, Lévesque P, Provencher D, Lea RH, Rosolowich V, Shapiro HM, Breast Disease Committee Executive Committee, Council and Society of Obstetricians and Gynaecologists of Canada. Breast cancer, pregnancy, and breastfeeding. J Obstet Gynaecol Can 2002;24:164-180.
79. Heshmati HM, Khosla S, Robins SP, O'Fallon WM, Melton LJ 3rd, Riggs BL. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002; 17:172-178.
80. Hickey M, Saunders CM, Partridge A, Santoro N, Joffe H, Stearns V. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 2008;19:1669-1680.
81. Higgins S, Haffty BG. Pregnancy and lactation after breast-conserving therapy for early stage breast cancer. Cancer 1994;73 2175-2180.
82. Holmberg L, Anderson H, and committees Hsadm. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: Trial stopped. Lancet 2004;363:453-455.
83. Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475-482.
84. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
85. Ives A, Saunders C, Bulsara M, Semmens J. Pregnancy after breast cancer: population based study. BMJ 2007;334:194.
86. Jasper MJ, Liebelt J, Hussey ND. Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth. Prenat Diagn 2008;28:292-298.
87. Jatoi I, Proschan MA. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: A pooled analysis of updated results. Am J Clin Oncol 2005;28:289-294.
88. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol 2007; 25:2921-2927.
89. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17:584-587.
90. Kil WJ, Ahn SD, Shin SS, Lee SW, Choi EK, Kim JH, Son BH, Ahn SH, Kim WK, Kim SB. Treatment-induced menstrual changes in very young (<35 years old) breast cancer patients. Breast Cancer Res Treat 2006;96 245-250.
91. Kim SH, Simkovich-Heerdt A, Tran KN, Maclean B, Borgen PI.Women 35 years of age or younger have higher locoregional relapse rates after undergoing breast conservation therapy. J Am Coll Surg 1998;187 1-8.
92. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007;8:881-888.
93. Kroman N, Jensen MB, Melbye M, Wohlfahrt J, Mouridsen HT. Should women be advised against pregnancy after breast-cancer treatment? Lancet 1997;350:319-322.
94. Kroman N, Holtveg H, Wohlfahrt J, Jensen M-B, Mouridsen HT, Blichert-Toft M, Melbye M. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 2004;100:688-693.
95. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K, American Society of Clinical O. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931.
96. Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP, Partridge AH. Menopausal-type symptoms in young breast cancer survivors. Ann Oncol 2006;17:1777-1782.
97. Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, Rahaman JA, Robson ME, Offit K, Barakat RR et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003;21:4222-4227.
98. Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 2001;93:1215-1223.
99. Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331:347-352.
100. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland KM Jr, Law M, Windschitl HE, Kaur JS, Ellison N. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15:969-973.
101. Loprinzi CL, Kugler JW, Barton DL, Dueck AC, Tschetter LK, Nelimark RA, Balcueva EP, Burger KN, Novotny PJ, Carlson MD et al. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol 2007;25 308-312.
102. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326 852-856.
103. Love RR, Van Dinh N, Quy TT, Linh ND, Tung ND, Shen T-Z, Hade EM, Young GS, Jarjoura D. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. J Clin Oncol 2008;26:253-257.
104. Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: Pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 2005;11:69-89.
105. MacLennan A, Lester S, Moore V. Oral oestrogen and combined oestrogen/ progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;18: CD002978.
106. Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 2006; 24:3576-3582.
107. Maggard MA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY. Do young breast cancer patients have worse outcomes? J Surg Res 2003; 113:109-113.
108. Malone K, Daling J, Neal C, Suter N, O'Brien C, Cushing-Haugen K, Jonasdottir T, Thompson J, Ostra E. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer Epidemiol Biomarkers Prev 2000;88:1393-1402.
109. Mansel R, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial. J Natl Cancer Inst 2006;98:599-609.
110. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla J-P, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352 2302-2313.
111. Mathias C, Cardeal Mendes CM, Pondé de Sena E, Dias de Moraes E, Bastos C, Braghiroli MI, Nuñez G, Athanazio R, Alban L, Moore HC et al. An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer. Ann Oncol 2006; 17:1792-1796.
112. McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007;8:26-34.
113. Metcalfe KA, Poll A, O'Connor A, Gershman S, Armel S, Finch A, Demsky R, Rosen B, Narod SA. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation. Clin Genet 2007;72:208-217.
114. Michels KB, Trichopoulos D, Rosner BA, Hunter DJ, Colditz GA, Hankinson SE, Speizer FE, Willett WC. Being breastfed in infancy and breast cancer incidence in adult life: Results from the two nurses' health studies. Am J Epidemiol 2001;153:275-283.
115. Mintzer D, Glassburn J, Mason BA, Sataloff D. Breast cancer in the very young patient: A multidisciplinary case presentation. Oncologist 2002; 7:547-554.
116. Moran MS, Colasanto JM, Haffty BG, Wilson LD, Lund MW, Higgins SA. Effects of breast-conserving therapy on lactation after pregnancy. Cancer J 2005;11:399-403.
117. Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: A review. Obstet Gynecol 2001;97:855-866.
118. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-180.
119. Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, Port E, Sacchini V, Sclafani L, VanZee K et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: A follow-up study of 4008 procedures. Ann Surg 2004;240:462-468; discussion 468-471.
120. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, Walker M, Humphrey L. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295 2057-2071.
121. Newman LA, Kuerer HM. Advances in breast conservation therapy. J Clin Oncol 2005;23:1685-1697.
122. Nguyen TV, Center JR, Eisman JA. Association between breast cancer and bone mineral density: The Dubbo Osteoporosis Epidemiology Study. Maturitas 2000;36:27-34.
123. Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol 2005;23:3858-3859.
124. Oktay K, Tilly J. Livebirth after cryopreserved ovarian tissue autotransplantation. Lancet 2004;364:2091-2092.
125. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: A prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005;23:4347-4353.
126. Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, Bang H. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006a;91:3885-3890.
127. Oktay K, Oktem O, Reh A, Vahdat L. Measuring the impact of chemotherapy on fertility in women with breast cancer. J Clin Oncol 2006b;24 4044-4046.
128. Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007; 110:2222-2229.
129. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949-955.
130. Pagani O, Goldhirsch A. Breast cancer in young women: Climbing for progress in care and knowledge. Women's Health 2006;2 717-732.
131. Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, Sweeney T, Banerjee TK, Flynn PJ. Gabapentin for hot flashes in 420 women with breast cancer: A randomised double-blind placebo-controlled trial. Lancet 2005;366:818-824.
132. Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, Rosenberg R, Przypyszny M, Rein A, Winer EP. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004; 22:4174-4183.
133. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 2007;43 1646-1653.
134. Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, Sukumvanich P. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol 2006;24:1045-1051.
135. Ponzone R, Biglia N, Jacomuzzi ME, Maggiorotto F, Mariani L, Sismondi P. Vaginal oestrogen therapy after breast cancer: Is it safe? Eur J Cancer 2005;41:2673-2681.
136. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
137. Prince RL. How to diagnose the presence of osteoporosis and assess the risk of fracture. Best Pract Res Clin Rheumatol 2001;15 345-358.
138. Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GKF, Mullan PB, Johnston PG, Wilson RH, Harkin DP. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007;13:7413-7420.
139. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CML, Weir L, Gelmon K et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005;97:116-126.
140. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: A critical review. J Clin Oncol 2008;26:2568-2581.
141. Rapiti E, Fioretta G, Verkooijen HM, Vlastos G, Schafer P, Sappino A-P, Kurtz J, Neyroud-Caspar I, Bouchardy C. Survival of young and older breast cancer patients in Geneva from 1990 to 2001. Eur J Cancer 2005;41:1446-1452.
142. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19:980-991.
143. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 2004; 22 1055-1062.
144. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van't Veer L et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 2005; 23 7804-7810.
145. Reichman BS, Green KB. Breast cancer in young women: Effect of chemotherapy on ovarian function, fertility, and birth defects. J Natl Cancer Inst Monogr 1994;16:125-129.
146. Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M, Mariotto A, Miller B, Feuer E, Altekruse S et al. SEER Cancer Statistics Review, 1975-2005. Natl Cancer Inst 2008. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/ (based on November 2007 SEER data submission, posted to the SEER web site).
147. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008;13:477-493.
148. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health
149. Rottenberg S, Nygren AOH, Pajic M, van Leeuwen FWB, van der Heijden I, van de Wetering K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen O et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 2007;104:12117-12122.
150. Sacchini V, Pinotti JA, Barros ACSD, Luini A, Pluchinotta A, Pinotti M, Boratto MG, Ricci MD, Ruiz CA, Nisida AC et al. Nipple-sparing mastectomy for breast cancer and risk reduction: Oncologic or technical problem? J Am Coll Surg 2006;203:704-714.
151. Sambrook PN, Eisman JA. Osteoporosis prevention and treatment. Med J Aust 2000;172:226-229.
152. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: 'healthy mother effect'. Am J Obstet Gynecol 1994;170:818-823.
153. Santoro N. What a SWAN can teach us about menopause. Contemp Obstet/ Gynecol 2004;49:69-79.
154. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14 2738-2746.
155. Schover LR. Sexuality and body image in younger women with breast cancer. J Natl Cancer Inst Monogr 1994;16:177-182.
156. Schulze T, Mucke J, Markwardt J, Schlag PM, Bembenek A. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol 2006;93:109-119.
157. Schwartz GF, Veronesi U, Clough KB, Dixon JM, Fentiman IS, Heywang-Kobrunner SH, Holland R, Hughes KS, Mansel RE, Margolese R et al. Consensus conference on breast conservation, Milan, Italy, April 28-May 1, 2005. Breast J 2006;12:398-407.
158. Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol 2006;24:3991-3996.
159. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306-3311.
160. Smith KR, Ellington L, Chan AY, Croyle RT, Botkin JR. Fertility intentions following testing for a BRCA1 gene mutation. Cancer Epidemiol Biomarkers Prev 2004;13:733-740.
161. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004;10:251-266.
162. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist 2006;11:422-434.
163. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-1764.
164. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006; 4 CD001500.
165. Sverrisdottir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2004;22:3694-3699.
166. Swain SM, Land SR, Sundry R, Ritter M, Costantino J, Wolmark N, Ganz PA. Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) docetaxel (T) arm of NSABP B-30: Preliminary results. J Clin Oncol 2005;23:13S-13S.
167. Tewari K, Bonebrake RG, Asrat T, Shanberg AM. Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet 1997;350:183.
168. Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007;30:126-132.
169. Thewes B, Meiser B, Taylor A, Phillips KA, Pendlebury S, Capp A, Dalley D, Goldstein D, Baber R. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol 2005;23:5155-5165.
170. Tralins AH. Lactation after conservative breast surgery combined with radiation therapy. Am J Clin Oncol 1995;18:40-43.
171. Trinh XB, Tjalma WAA, Makar AP, Buytaert G, Weyler J, van Dam PA. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril 2008;90:17-22.
172. Truong PT, Olivotto IA, Kader HA, Panades M, Speers CH, Berthelet E. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2005;61:1337-1347.
173. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-452.
174. Velentgas P, Daling JR, Malone KE, Weiss NS, Williams MA, Self SG, Mueller BA. Pregnancy after breast carcinoma: Outcomes and influence on mortality. Cancer 1999;85:2424-2432.
175. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Maisonneuve P, Gatti G et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 2006;7 983-990.
176. von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: The Stockholm randomized trial. J Natl Cancer Inst 2005; 97:533-535.
177. Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, van Tienhoven G, Andersen KW, Sylvester RJ, van Dongen JA et al Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage J and II breast cancer: Pooled results of two large European randomized trials [erratum appears in J Clin Oncol 2001 May 1; 19(9):2583]. J Clin Oncol 2001;19:1688-1697.
178. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Bing Oei S, Peterse HL, Pierart M, Poortmans PM et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer 2003;39:932-944.
179. Weiss SM, Wengert PA Jr, Martinez EM, Sewall W, Kopp E. Patient satisfaction with decision-making for breast cancer therapy. Ann Surg Oncol 1996;3:285-289.
180. Weitzel J, McCaffrey S, Nedelcu R, MacDonald D, Blazer K, Cullinane C. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 2003;138:1323-1328; discussion 1329.
181. White JR, Halberg FE, Rabinovitch R, Green S, Haffty BG, Solin LJ, Strom EA, Taylor ME, Edge SB. American College of Radiology appropriateness criteria on conservative surgery and radiation: Stages I and II breast carcinoma. J Am Coll Radiol 2008;5:701-713.
182. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, Santoro N. Androgen therapy in women: An Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006;91:3697-3710.
183. Yang SH, Yang KH, Li YP, Zhang YC, He XD, Song AL, Tian JH, Jiang L, Bai ZG, He LF et al. Breast conservation therapy for stage I or stage II breast cancer: A meta-analysis of randomized controlled trials. Ann Oncol 2008;19:1039-1044.
184. Zhou P, Recht A. Young age and outcome for women with early-stage invasive breast carcinoma. Cancer 2004;101:1264-1274.